Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCVAC/OvCa in newly diagnosed epithelial ovarian carcinoma
NCT02107937Phase 2Completed
- Sponsor
- SOTIO Biotech
- Start
- Nov 2013
- Primary completion
- Nov 2020
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of DCVAC/OvCa in epithelial ovarian carcinoma (EOC) (3 arms), sponsored by SOTIO Biotech. Primary endpoint: Overall Progression Free Survival at 104 weeks. Started Nov 2013; status: completed.
02
Drugs
DCVAC/OvCa
03
Conditions
epithelial ovarian carcinoma (EOC)
Beyond the preview
Go deeper on NCT02107937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02107937.